Lan Jiang

US Patent:

7396933, Jul 8, 2008

Filed:

Nov 4, 2005

Appl. No.:

11/267720

Inventors:

Seok-Ki Choi - Palo Alto CA, US
Paul Fatheree - San Francisco CA, US
Roland Gendron - San Francisco CA, US
Adam A Goldblum - San Francisco CA, US
Lan Jiang - Foster City CA, US
Daniel D Long - San Francisco CA, US
Daniel Marquess - Half Moon Bay CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

C07D 215/00

US Classification:

546156

Abstract:

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

US Patent:

7399862, Jul 15, 2008

Filed:

Nov 4, 2005

Appl. No.:

11/266881

Inventors:

Seok-Ki Choi - Palo Alto CA, US
Paul Fatheree - San Francisco CA, US
Adam A Goldblum - San Francisco CA, US
Lan Jiang - Foster City CA, US
Daniel D Long - San Francisco CA, US
Daniel Marquess - Half Moon Bay CA, US
S. Derek Turner - San Francisco CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

C07D 215/00

US Classification:

546156

Abstract:

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

US Patent:

7498442, Mar 3, 2009

Filed:

Mar 13, 2008

Appl. No.:

12/075740

Inventors:

Seok-Ki Choi - Palo Alto CA, US
Paul Fatheree - San Francisco CA, US
Roland Gendron - San Francisco CA, US
Adam A Goldblum - San Francisco CA, US
Lan Jiang - Foster City CA, US
Daniel D Long - San Francisco CA, US
Daniel Marquess - Half Moon Bay CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

C07D 215/00
C07D 471/02

US Classification:

546156, 546123

Abstract:

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

US Patent:

7534889, May 19, 2009

Filed:

Jun 11, 2008

Appl. No.:

12/136891

Inventors:

Seok-Ki Choi - Palo Alto CA, US
Paul Fatheree - San Francisco CA, US
Adam A Goldblum - San Francisco CA, US
Lan Jiang - Foster City CA, US
Daniel D Long - San Francisco CA, US
Daniel Marquess - Half Moon Bay CA, US
S. Derek Turner - San Francisco CA, US

Assignee:

Theravance, Inc. - South San Francisco CA

International Classification:

C07D 215/00
A01N 43/90

US Classification:

546156, 514305

Abstract:

The invention provides novel quinolinone-carboxamide 5-HTreceptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HTreceptor activity, and processes and intermediates useful for preparing such compounds.

US Patent:

20140080855, Mar 20, 2014

Filed:

Jun 10, 2013

Appl. No.:

13/914093

Inventors:

Daisuke Roland Saito - San Mateo CA, US
Daniel D. Long - San Francisco CA, US
Lan Jiang - Foster City CA, US
Bryan Frieman - San Diego CA, US

Assignee:

THERAVANCE, INC. - South San Francisco CA

International Classification:

C07D 451/02
A61K 31/485
A61K 31/46

US Classification:

514282, 546124, 514304

Abstract:

The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I):wherein R, R, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

US Patent:

20220306624, Sep 29, 2022

Filed:

Mar 7, 2022

Appl. No.:

17/688001

Inventors:

- South san Francisco CA, US
John R. Jacobsen - San Mateo CA, US
Anne-Marie Beausoleil - Redwood City CA, US
Gary E.L. Brandt - Alameda CA, US
Melissa Fleury - Brisbane CA, US
Lan Jiang - Foster City CA, US
Cameron Smith - San Bruno CA, US
Steven D.E. Sullivan - San Francisco CA, US
Lori Jean Van Orden - San Francisco CA, US
Pierre-Jean Colson - San Francisco CA, US
Gene Timothy Fass - San Francisco CA, US
Miroslav Rapta - San Carlos CA, US
Noah Benjamin - San Francisco CA, US
Marta Dabros - Foster City CA, US
Venkat R. Thalladi - Foster City CA, US

Assignee:

THERAVANCE BIOPHARMA R&D IP, LLC - South San Francisco CA

International Classification:

C07D 471/04
A61K 31/437
A61K 31/416
A61P 43/00
A61P 11/06
A61P 11/00

Abstract:

The invention provides compounds of formula (I):wherein X isand the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

US Patent:

20220267343, Aug 25, 2022

Filed:

Jan 18, 2022

Appl. No.:

17/578020

Inventors:

- Foster City CA, US
Ana Z. Gonzalez Buenrostro - San Mateo CA, US
Hongyan Guo - San Mateo CA, US
Xiaochun Han - San Jose CA, US
Anna E. Hurtley - San Mateo CA, US
Lan Jiang - Foster City CA, US
Jiayao Li - Foster City CA, US
David W. Lin - Berkeley CA, US
Michael L. Mitchell - Castro Valley CA, US
Devan Naduthambi - San Bruno CA, US
Gregg M. Schwarzwalder - Redwood City CA, US
Suzanne M. Szewczyk - San Mateo CA, US
Matthew J. Von Bargen - Redwood City CA, US
Qiaoyin Wu - Foster City CA, US
Hong Yang - Fremont CA, US
Jennifer R. Zhang - Union City CA, US

International Classification:

C07D 487/18
C07D 487/22
C07D 491/22
A61P 31/18

Abstract:

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

US Patent:

20230027019, Jan 26, 2023

Filed:

Jun 29, 2021

Appl. No.:

17/361758

Inventors:

- Foster City CA, US
Ana Z. Gonzalez Buenrostro - San Mateo CA, US
Hongyan Guo - San Mateo CA, US
Xiaochun Han - San Jose CA, US
Lan Jiang - Foster City CA, US
Jiayao Li - Foster City CA, US
Michael L. Mitchell - Castro Valley CA, US
Hyung-Jung Pyun - Fremont CA, US
Scott D. Schroeder - Union City CA, US
Gregg M. Schwarzwalder - Redwood City CA, US
Nathan D. Shapiro - Belmont CA, US
Devleena M. Shivakumar - Menlo Park CA, US
Qiaoyin Wu - Foster City CA, US
Hong Yang - Fremont CA, US
Jennifer R. Zhang - Union City CA, US

International Classification:

C07D 498/18
C07D 471/18
A61P 31/18

Abstract:

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I):including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.